97 related articles for article (PubMed ID: 35238345)
1. How I Diagnose Primary Myelofibrosis.
Prakash S; Orazi A
Am J Clin Pathol; 2022 Apr; 157(4):518-530. PubMed ID: 35238345
[TBL] [Abstract][Full Text] [Related]
2. Understanding triple negative myeloproliferative neoplasms: pathogenesis, clinical features, and management.
Tharakan S; Mascarenhas J; Tremblay D
Leuk Lymphoma; 2024 Feb; 65(2):158-167. PubMed ID: 38033130
[No Abstract] [Full Text] [Related]
3. Genome-wide DNA methylation profiling is able to identify prefibrotic PMF cases at risk for progression to myelofibrosis.
Lehmann U; Stark H; Bartels S; Schlue J; Büsche G; Kreipe H
Clin Epigenetics; 2021 Feb; 13(1):28. PubMed ID: 33541399
[TBL] [Abstract][Full Text] [Related]
4. STAT5a and SH2B3 novel mutations display malignancy roles in a triple-negative primary myelofibrosis patient.
Zhang S; Yan J; He L; Jiang Z; Jiang H
Cancer Gene Ther; 2024 Mar; 31(3):484-494. PubMed ID: 38135698
[TBL] [Abstract][Full Text] [Related]
5. In utero origin of myelofibrosis presenting in adult monozygotic twins.
Sousos N; Ní Leathlobhair M; Simoglou Karali C; Louka E; Bienz N; Royston D; Clark SA; Hamblin A; Howard K; Mathews V; George B; Roy A; Psaila B; Wedge DC; Mead AJ
Nat Med; 2022 Jun; 28(6):1207-1211. PubMed ID: 35637336
[TBL] [Abstract][Full Text] [Related]
6. Proteogenetic drug response profiling elucidates targetable vulnerabilities of myelofibrosis.
Wildschut MHE; Mena J; Dördelmann C; van Oostrum M; Hale BD; Settelmeier J; Festl Y; Lysenko V; Schürch PM; Ring A; Severin Y; Bader MS; Pedrioli PGA; Goetze S; van Drogen A; Balabanov S; Skoda RC; Lopes M; Wollscheid B; Theocharides APA; Snijder B
Nat Commun; 2023 Oct; 14(1):6414. PubMed ID: 37828014
[TBL] [Abstract][Full Text] [Related]
7. [Pathogenic role of insufficiency of polycomb repressive complex in primary myelofibrosis].
Shinoda D
Rinsho Ketsueki; 2023; 64(9):998-1006. PubMed ID: 37793876
[TBL] [Abstract][Full Text] [Related]
8. Clonal evolution revealed by whole genome sequencing in a case of primary myelofibrosis transformed to secondary acute myeloid leukemia.
Engle EK; Fisher DA; Miller CA; McLellan MD; Fulton RS; Moore DM; Wilson RK; Ley TJ; Oh ST
Leukemia; 2015 Apr; 29(4):869-76. PubMed ID: 25252869
[TBL] [Abstract][Full Text] [Related]
9. CALR mutations possess unique prognostic relevance in myelofibrosis-before and after transplant.
Tefferi A; Vannucchi AM
Bone Marrow Transplant; 2024 Jan; 59(1):1-3. PubMed ID: 37821534
[No Abstract] [Full Text] [Related]
10. Myeloproliferative Neoplasms: Contemporary Review and Molecular Landscape.
Mahmud M; Vasireddy S; Gowin K; Amaraneni A
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139212
[TBL] [Abstract][Full Text] [Related]
11. Leukemic conversion involving
Gurban P; Mambet C; Botezatu A; Necula LG; Neagu AI; Matei L; Pitica IM; Nedeianu S; Chivu-Economescu M; Bleotu C; Ataman M; Mocanu G; Saguna C; Pavel AG; Stambouli D; Sepulchre E; Anton G; Diaconu CC; Constantinescu SN
Front Oncol; 2023; 13():1266996. PubMed ID: 37841434
[TBL] [Abstract][Full Text] [Related]
12. First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis.
Crespiatico I; Zaghi M; Mastini C; D'Aliberti D; Mauri M; Mercado CM; Fontana D; Spinelli S; Crippa V; Inzoli E; Manghisi B; Civettini I; Ramazzotti D; Sangiorgio V; Gengotti M; Brambilla V; Aroldi A; Banfi F; Barone C; Orsenigo R; Riera L; Riminucci M; Corsi A; Breccia M; Morotti A; Cilloni D; Roccaro A; Sacco A; Stagno F; Serafini M; Mottadelli F; Cazzaniga G; Pagni F; Chiarle R; Azzoni E; Sessa A; Gambacorti-Passerini C; Elli EM; Mologni L; Piazza R
Blood; 2024 Apr; 143(14):1399-1413. PubMed ID: 38194688
[TBL] [Abstract][Full Text] [Related]
13. A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF).
Bejanyan N; Tiu RV; Raza A; Jankowska A; Kalaycio M; Advani A; Chan J; Saunthararajah Y; Mooney L; Maciejewski JP; Sekeres MA
Cancer; 2012 Aug; 118(16):3968-76. PubMed ID: 22180010
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies.
Zahr AA; Salama ME; Carreau N; Tremblay D; Verstovsek S; Mesa R; Hoffman R; Mascarenhas J
Haematologica; 2016 Jun; 101(6):660-71. PubMed ID: 27252511
[TBL] [Abstract][Full Text] [Related]
15. CCN2/CTGF expression does not correlate with fibrosis in myeloproliferative neoplasms, consistent with noncanonical TGF-β signaling driving myelofibrosis.
Leguit RJ; Broekhuizen R; de Witte M; Raymakers RAP; Goldschmeding R
Virchows Arch; 2024 Apr; ():. PubMed ID: 38602559
[TBL] [Abstract][Full Text] [Related]
16. Deregulation of the p19/CDK4/CDK6 axis in Jak2
Duparc H; Muller D; Gilles L; Chédeville AL; El Khoury M; Guignard R; Debili N; Wittner M; Kauskot A; Pasquier F; Antony-Debré I; Marty C; Vainchenker W; Plo I; Raslova H
Leukemia; 2024 Apr; 38(4):898-902. PubMed ID: 38378843
[No Abstract] [Full Text] [Related]
17. Overt primary myelofibrosis with coexistence of JAK2V617F and MPLW515R driver mutations.
Wang Y; Fan D; Zhang X
Int J Lab Hematol; 2024 Feb; 46(1):180-182. PubMed ID: 37822120
[No Abstract] [Full Text] [Related]
18. CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis.
Dunbar AJ; Kim D; Lu M; Farina M; Bowman RL; Yang JL; Park Y; Karzai A; Xiao W; Zaroogian Z; O'Connor K; Mowla S; Gobbo F; Verachi P; Martelli F; Sarli G; Xia L; Elmansy N; Kleppe M; Chen Z; Xiao Y; McGovern E; Snyder J; Krishnan A; Hill C; Cordner K; Zouak A; Salama ME; Yohai J; Tucker E; Chen J; Zhou J; McConnell T; Migliaccio AR; Koche R; Rampal R; Fan R; Levine RL; Hoffman R
Blood; 2023 May; 141(20):2508-2519. PubMed ID: 36800567
[TBL] [Abstract][Full Text] [Related]
19. The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis.
Hernández-Sánchez A; Villaverde-Ramiro Á; Arellano-Rodrigo E; Garrote M; Martín I; Mosquera-Orgueira A; Gómez-Casares MT; Ferrer-Marín F; Such E; Velez P; Ayala R; Angona A; de Las Heras N; Magro E; Mata-Vázquez MI; Fox ML; de Villambrosía SG; Ramírez MJ; García A; García-Gutiérrez V; Cáceres A; Durán MA; Senín A; Raya JM; González JA; Cuevas B; Xicoy B; Pérez-Encinas M; Bellosillo B; Álvarez-Larrán A; Hernández-Rivas JM; Hernández-Boluda JC;
Am J Hematol; 2024 Apr; 99(4):755-758. PubMed ID: 38291566
[TBL] [Abstract][Full Text] [Related]
20. Pulmonary hypertension with massive megalosplenia: A case report.
Yi T; Ma W; Qiu J; Ding W
Medicine (Baltimore); 2019 Mar; 98(12):e14594. PubMed ID: 30896614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
